Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 17, 2012, Pages 5681-5684

  Miyata, Junji ^a   Kasahara, Chiyoshi ^a   Asano, Toru ^a   Ito, Shinji ^a   Seki, Norio ^a   Kato, Yasuko ^a   Morikawa, Noriyuki ^a   Nozaki, Kazuyoshi ^a   Nishimura, Kouji ^b   Akamatsu, Hisashi ^b   Taguchi, Yusuke ^b   Yamaguchi, Tomonori ^b   Abe, Yoshito ^a   Ohkubo, Mitsuru ^a   Watanabe, Toshihiro ^a   Ohta, Mitsuaki ^a   Takeuchi, Makoto ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b WAKUNAGA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Benzyl; Inhibitor; Osteoclastogenesis; Pyrimidine; RANKL

Indexed keywords

4 PYRROLDINO 2 (PYRIDIN 2 YL)PYRIMIDINE; OSTEOCLAST DIFFERENTIATION FACTOR; PYRIMIDINE DERIVATIVE; RALOXIFENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG IDENTIFICATION; FEMALE; FLUORINATION; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; MICROSOME; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOPENIA; RAT;

ADMINISTRATION, ORAL; ANIMALS; BONE RESORPTION; CELL LINE; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICROSOMES; OSTEOCLASTS; PYRIDINES; PYRIMIDINES; RANK LIGAND; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS; RODENTIA;

EID: 84865131678     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.06.087     Document Type: Article

References (25)

1. W.J. Boyle, W.S. Simonet, and D.L. Lacey Nature 423 2003 337
2. S.L. Teitelbaum Science 289 2000 1504
3. T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M.T. Gillespie, and T.J. Martin Endocr. Rev. 20 1999 345
4. N.S. Soyas, and N. Alles Biochem. Biophys. Res. Commun. 378 2009 1
5. J. Jules, J.W. Ashley, and X. Feng Expert Opin. Ther. Targets 14 2010 923
6. J. Allen, C. Fotsch, and P. Babij J. Med. Chem. 53 2010 177
7. E. Terpos, E. Efstathiou, D. Christoulas, M. Roussou, E. Katodritou, and M.A. Dimopoulos Expert Opin. Biol. Ther. 9 2009 465
8. G.R. Mundy Nutr. Rev. 65 2007 S147
9. D.W. Demper, C.L. Lambing, P.J. Kostenuik, and A. Grauer Clin. Ther. 34 2012 521
10. J.R. Nangia, J.D. Ma, C.M. Nguyen, M.A. Mendes, and M.V. Trivedi Expert. Opin. Biol. Ther. 12 2012 491
11. E. Tsourdi, T.D. Rachner, M. Rauner, C. Hamann, and L.C. Hofbauer Eur. J. Endocrinol. 165 2011 833
12. S.B. Cohen, R.K. Dore, N.E. Lane, P.A. Ory, C.G. Peterfy, J.T. Sharp, D. van der Heijde, L. Zhou, W. Tsuji, and R. Newmark Arthritis Rhuem. 58 2008 1299
13. R.G. Russell, N.B. Watts, F.H. Ebetino, and M.J. Rogers Osteoporos. Int. 19 2008 733
14. P.F. Conte, and V. Guarneri Oncologist 9 2004 28
15. O. Filleul, E. Crompot, and S. Saussez J. Cancer Res. Clin. Oncol. 136 2010 1117
16. C.H. Tseng, R.W. Lin, Y.L. Chen, G.J. Wang, M.L. Ho, and C.C. Tzeng J. Med. Chem. 54 2011 3103
17. J. Xu, Z. Li, J. Luo, F. Yang, T. Liu, M. Liu, W. Qui, and J. Tang J. Med. Chem. 55 2012 3122
18. C. Li, Z. Yang, Z. Li, Y. Ma, L. Zhang, C. Zheng, W. Qiu, X. Wu, X. Wang, H. Li, J. Tang, M. Qian, D. Li, P. Wang, J. Luo, and M. Liu J. Bone Miner. Res. 26 2011 644
19. M. Zhu, M.H. Kim, S. Lee, S.J. Bae, S.H. Kim, and S.B. Park J. Med. Chem. 53 2010 8760
20. J.H. Lee, H.N. Kim, D. Yang, K. Jung, H.M. Kim, H.H. Kim, and H. Ha J. Biol. Chem. 284 2009 13725
21. I.R. Greig, A.I. Idris, S.H. Ralston, and R.J. Van't Hof J. Med. Chem. 49 2006 7487
22. T. Chen, A.C. Knapp, Y. Wu, J. Huang, J.S. Lynch, J. Dickson, R.M. Lawrence Jr., J.H.M. Feyen, and M.L. Agler Assay Drug Dev. Technol. 4 2006 387
23. E. Negishi Acc. Chem. Res. 15 1982 340
24. Y. Tomimori, K. Mori, M. Koide, Y. Nakamichi, T. Ninomiya, N. Udagawa, and H. Yasuda J. Bone Miner. Res. 24 2009 1194 1205
25. Protein kinase panel assay of compounds 22 and 23 showed <40% inhibition against 93 of all tested kinases at 10 μM.